Literature DB >> 25400438

Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Yoshihisa Takahashi1, Toshio Fukusato1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome, is the most common chronic liver disease, and the prevalence is rapidly increasing worldwide. Nonalcoholic steatohepatitis (NASH), the severe form of NAFLD, can progress to liver cirrhosis and hepatocellular carcinoma (HCC). Although noninvasive clinical scores and image-based diagnosis for NAFLD have improved, histopathological evaluation of biopsy specimens remains the gold standard for diagnosing NAFLD/NASH. Steatosis, lobular inflammation, and hepatocellular ballooning are all necessary components for the diagnosis of NASH; fibrosis is also typically observed. Other histopathological abnormalities commonly observed in NASH include hepatocellular glycogenated nuclei, lipogranulomas, and acidophil bodies. The characteristics of pediatric NAFLD/NASH differ from adult NAFLD/NASH. Specifically, steatosis and portal inflammation are more severe in pediatric NAFLD, while intralobular inflammation and perisinusoidal fibrosis are milder. Although interobserver agreement for evaluating the extent of steatosis and fibrosis is high, agreement is low for intralobular and portal inflammation. A recently reported histological variant of HCC, steatohepatitic HCC (SH-HCC), shows features that resemble non-neoplastic steatohepatitis, and is thought to be strongly associated with underlying NASH. In this report, we review the histopathological features of NAFLD/NASH.

Entities:  

Keywords:  Histopathology; Interobserver variation; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pediatric

Mesh:

Year:  2014        PMID: 25400438      PMCID: PMC4229519          DOI: 10.3748/wjg.v20.i42.15539

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  64 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.

Authors:  Marcela Salomao; Woojin M Yu; Robert S Brown; Jean C Emond; Jay H Lefkowitch
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

3.  Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease.

Authors:  Sweta Tandra; Matthew M Yeh; Elizabeth M Brunt; Raj Vuppalanchi; Oscar W Cummings; Aynur Ünalp-Arida; Laura A Wilson; Naga Chalasani
Journal:  J Hepatol       Date:  2010-12-21       Impact factor: 25.083

Review 4.  Apoptosis in alcoholic and nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Gregory J Gores
Journal:  Front Biosci       Date:  2005-09-01

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.

Authors:  A Poonawala; S P Nair; P J Thuluvath
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Authors:  Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

9.  Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.

Authors:  H C Pinto; A Baptista; M E Camilo; A Valente; A Saragoça; M C de Moura
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

10.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

View more
  90 in total

1.  Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy.

Authors:  Jie Yan; Yang Yu; Jeon Woong Kang; Zhi Yang Tam; Shuoyu Xu; Eliza Li Shan Fong; Surya Pratap Singh; Ziwei Song; Lisa Tucker-Kellogg; Peter T C So; Hanry Yu
Journal:  J Biophotonics       Date:  2017-06-21       Impact factor: 3.207

2.  Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease.

Authors:  Benjamin Wolfson; Pang-Kuo Lo; Yuan Yao; Linhao Li; Hongbing Wang; Qun Zhou
Journal:  Mol Nutr Food Res       Date:  2018-06-12       Impact factor: 5.914

3.  Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.

Authors:  Tian Shen; Bilin Xu; Tao Lei; Lin Chen; Cuiping Zhang; Zhenhua Ni
Journal:  Exp Ther Med       Date:  2018-08-01       Impact factor: 2.447

4.  Long-Term, Fructose-Induced Metabolic Syndrome-Like Condition Is Associated with Higher Metabolism, Reduced Synaptic Plasticity and Cognitive Impairment in Octodon degus.

Authors:  Daniela S Rivera; Carolina B Lindsay; Juan F Codocedo; Laura E Carreño; Daniel Cabrera; Marco A Arrese; Carlos P Vio; Francisco Bozinovic; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2018-04-13       Impact factor: 5.590

5.  Serum Amyloid P and a Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin Ligand Inhibit High-Fat Diet-Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice.

Authors:  Darrell Pilling; Nehemiah Cox; Megan A Thomson; Tejas R Karhadkar; Richard H Gomer
Journal:  Am J Pathol       Date:  2019-09-18       Impact factor: 4.307

Review 6.  Circadian rhythms of liver physiology and disease: experimental and clinical evidence.

Authors:  Yu Tahara; Shigenobu Shibata
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

7.  Adelmidrol protects against non-alcoholic steatohepatitis in mice.

Authors:  Mahitab Mohamed Nageeb; Monira Ismaeil Khatab; Ahmed Ahmed Abdel-Sameea; Noha Abbas Teleb
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000

8.  Unexpected metabolic disorders induced by endocrine disruptors in Xenopus tropicalis provide new lead for understanding amphibian decline.

Authors:  Christophe Regnault; Marie Usal; Sylvie Veyrenc; Karine Couturier; Cécile Batandier; Anne-Laure Bulteau; David Lejon; Alexandre Sapin; Bruno Combourieu; Maud Chetiveaux; Cédric Le May; Thomas Lafond; Muriel Raveton; Stéphane Reynaud
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

9.  Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis.

Authors:  Takao Nagashima; Yasuyuki Kamata; Masahiro Iwamoto; Hitoaki Okazaki; Noriyoshi Fukushima; Seiji Minota
Journal:  Rheumatol Int       Date:  2019-02-21       Impact factor: 2.631

10.  High Prevalence of Hepatic Fibrosis, Measured by Elastography, in a Population-Based Study of Mexican Americans.

Authors:  Gordon P Watt; Miryoung Lee; Jen-Jung Pan; Michael B Fallon; Rohit Loomba; Laura Beretta; Joseph B McCormick; Susan P Fisher-Hoch
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-11       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.